Literature DB >> 25536484

Rheumatoid arthritis in 2014: Exciting times for RA research.

Paul Emery1.   

Abstract

2014 saw the emergence of a novel rheumatoid arthritis therapy to rival methotrexate, as well as advances in our understanding of mouse T.cell biology and of the cross-talk between the nervous system and the immune system. How will these advances affect the future of rheumatoid arthritis research and therapy?

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25536484     DOI： 10.1038/nrrheum.2014.216

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


  10 in total

1.  Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis.

Authors:  A Thiolat; L Semerano; Y M Pers; J Biton; D Lemeiter; P Portales; J Quentin; C Jorgensen; P Decker; M-C Boissier; P Louis-Plence; N Bessis
Journal:  Arthritis Rheumatol       Date:  2014-02       Impact factor: 10.995

2.  Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Authors:  R Maini; E W St Clair; F Breedveld; D Furst; J Kalden; M Weisman; J Smolen; P Emery; G Harriman; M Feldmann; P Lipsky
Journal:  Lancet       Date:  1999-12-04       Impact factor: 79.321

3.  Denervation protects limbs from inflammatory arthritis via an impact on the microvasculature.

Authors:  Lars Stangenberg; Dalia Burzyn; Bryce A Binstadt; Ralph Weissleder; Umar Mahmood; Christophe Benoist; Diane Mathis
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-21       Impact factor: 11.205

4.  A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.

Authors:  P Emery; F C Breedveld; E M Lemmel; J P Kaltwasser; P T Dawes; B Gömör; F Van Den Bosch; D Nordström; O Bjorneboe; R Dahl; K Horslev-Petersen; A Rodriguez De La Serna; M Molloy; M Tikly; C Oed; R Rosenburg; I Loew-Friedrich
Journal:  Rheumatology (Oxford)       Date:  2000-06       Impact factor: 7.580

Review 5.  New therapies for treatment of rheumatoid arthritis.

Authors:  Josef S Smolen; Daniel Aletaha; Marcus Koeller; Michael H Weisman; Paul Emery
Journal:  Lancet       Date:  2007-12-01       Impact factor: 79.321

6.  Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis.

Authors:  Noriko Komatsu; Kazuo Okamoto; Shinichiro Sawa; Tomoki Nakashima; Masatsugu Oh-hora; Tatsuhiko Kodama; Sakae Tanaka; Jeffrey A Bluestone; Hiroshi Takayanagi
Journal:  Nat Med       Date:  2013-12-22       Impact factor: 53.440

7.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Authors:  Jonathan C W Edwards; Leszek Szczepanski; Jacek Szechinski; Anna Filipowicz-Sosnowska; Paul Emery; David R Close; Randall M Stevens; Tim Shaw
Journal:  N Engl J Med       Date:  2004-06-17       Impact factor: 91.245

8.  Tofacitinib versus methotrexate in rheumatoid arthritis.

Authors:  Eun Bong Lee; Roy Fleischmann; Stephen Hall; Bethanie Wilkinson; John D Bradley; David Gruben; Tamas Koncz; Sriram Krishnaswami; Gene V Wallenstein; Chuanbo Zang; Samuel H Zwillich; Ronald F van Vollenhoven
Journal:  N Engl J Med       Date:  2014-06-19       Impact factor: 91.245

9.  Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig.

Authors:  Joel M Kremer; Rene Westhovens; Marc Leon; Eduardo Di Giorgio; Rieke Alten; Serge Steinfeld; Anthony Russell; Maxime Dougados; Paul Emery; Isaac F Nuamah; G Rhys Williams; Jean-Claude Becker; David T Hagerty; Larry W Moreland
Journal:  N Engl J Med       Date:  2003-11-13       Impact factor: 91.245

Review 10.  Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses.

Authors:  Shimon Sakaguchi
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527
  10 in total
  2 in total

1.  Design, synthesis and evaluation of (R)-3-(7-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-5-azaspiro[2.4]heptan-5-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor.

Authors:  Chieyeon Chough; Sunmin Lee; Misuk Joung; Jaemin Lee; Jong Hoon Kim; B Moon Kim
Journal:  Medchemcomm       Date:  2018-01-15       Impact factor: 3.597

2.  The Effects of Rituximab on Lipids, Arterial Stiffness and Carotid Intima-Media Thickness in Rheumatoid Arthritis.

Authors:  Diana S Novikova; Tatiana V Popkova; Galina V Lukina; Elena L Luchikhina; Dmitry E Karateev; Alexander V Volkov; Alexander A Novikov; Elena N Aleksandrova; Evgeny L Nasonov
Journal:  J Korean Med Sci       Date:  2016-01-14       Impact factor: 2.153
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.